New antimicrobial agents that hold promise against HIV and other sexually transmitted diseases are now being tested. Agents include Acidform, BufferGel and dapivirine.
Our goal here is to review the various microbicides currently being tested, outlining their mechanism of action, potential usefulness, and safety profile.
A spermicide with little or no microbicidal properties
Unfortunately research proved the agent less than ideal.3 Beginning in 1990, randomized controlled trials compared different N-9 formulations-sponge, film, and various gels-and dosages3-7 for their efficacy against HIV and other STDs. Taken together, these studies showed little if any protection against HIV, gonorrhea, and chlamydia. In one trial, women who used N-9 gel actually had higher rates of HIV than women using placebo gel.8
How do microbicides work?
Another polyanion gel-Pro2000/5-is currently being evaluated in large-scale effectiveness trials, which should have evidence within a year. The higher dose arm (2%) of Pro2000/5 was halted in February because the data could not show it was effective. The lower dose (0.5%) is continuing to be evaluated in two separate trials. Pro2000/5 may also have contraceptive activity. Another potential group of contraceptives, dendrimers, such as VivaGel, are highly branched macromolecules that also prevent HIV from attaching to the target cells.10 VivaGel is currently in safety studies.
While polyanions are nonspecific in the way they work, several HIV-specific entry/fusion inhibitors are also in development as microbicides, including drugs that block gp-41 fusions and CCR5-receptor binding.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More